Kornimate/medical-research-clean huggingface dataset:
feasibility of use of baricare app in pre-bariatric surgery.

Conditions: Obesity

Summary: this current study aims to evaluate the efficacy of engagement modules in preparing patients for bariatric surgery. with the help of the center for innovation (cfi), a smartphone app (android and apple compatible) has been created that will assist in both educating and engaging patients to develop and maintain healthy lifestyle modifications. our goal is to create a cost-effective, smartphone-based platform that serves to not only efficiently educate but to also verify competence and keep our patients engaged during the lengthy pre-bariatric surgery process.


Eligibility criteria:
inclusion criteria: 1. patients, who upon completion of an evaluation by endocrinology, are considered appropriate to pursue a primary, laparoscopic bariatric surgery. 2. patients who are 18 years of age or greater. 3. patients who own a smartphone. exclusion criteria: 1. patients with a history of a prior bariatric surgery. 2. patients with active psychiatric disorder(s). 3. patients with active tobacco use. 4. patients with active substance use (alcohol, illicit drugs, etc.)
an open-label extension study of psma adc 2301 in mcrpc

Conditions: Prostate Cancer

Summary: psma adc 2301ext is an open-label study to further assess the anti-tumor activity as measured by radiographic imaging and biomarkers, safety and tolerability of prostate specific membrane antigen antibody drug conjugate (psma adc) in subjects with mcrpc. subjects who have participated in the psma adc 2301 study and who, in the opinion of the principal investigator are likely to benefit from continued treatment with psma adc are eligible for the psma adc 2301 extension study. subjects who are benefiting from treatment may be able to receive up to an additional eight to sixteen doses (every 3 weeks) of psma adc.


Eligibility criteria:
inclusion criteria: 1. subjects who have completed the psma adc 2301 study and who, in the opinion of the investigator, are likely to benefit from continued treatment with psma adc 2. eastern cooperative oncology group (ecog) performance status of 0, 1, or 2 3. if chemically castrated, subjects must agree to stay on androgen-deprivation therapy for the duration of the study 4. if applicable, men must agree to commit to the use of a medically acceptable method of birth control (e.g., spermicide in conjunction with a barrier such as a condom) or sexual abstinence for the duration of the study, including 30 days after the last dose of study drug exclusion criteria: 1. an acute infection requiring ongoing antibiotic therapy (e.g., uti, indwelling catheter or other potential site(s) of infection) 2. history of significant hypersensitivity reactions to psma adc or any of its components, or to any prior investigational or approved monoclonal antibodies (mabs), immunoglobulin (ig) fusion proteins (e.g., circulating neutralizing antibodies), or adc 3. clinically significant cardiac disease or severe debilitating pulmonary disease 4. any recent or ongoing medical condition that may interfere with a subject's participation or compliance with the study or evaluation of psma adc
intrathoracic chemotherapy for tets with pleural spread or recurrence

Conditions: Thymic Epithelial Tumor

Summary: hyperthermic intrathoracic chemotherapy (hitoc) offers an additional treatment option for malignant pleural tumors after surgical cytoreduction. especially it is used to further improve local tumor control in thymic malignancies with pleural spread, who underwent multimodality therapy including surgical resection. a phase ii clinical study was conducted to explore the efficacy and safety of surgery followed by hitoc (pod1: dox, pod2: cisplatin) for thymic epithelial tumors with pleural spread or recurrence.


Eligibility criteria:
inclusion criteria: 1. puncture biopsy, thoracoscopic/mediastinal biopsy, or surgery to confirm pathologically thymic epithelial tumor (tets) 2. imaging examination shows tets with pleural spread or recurrence, and the mediastinal mdt team considers hitoc suitable. 3. patients with ≥16 and ≤80 years old. 4. asa i-ii. 5. the patients should have no functional disorders in the main organs. 6. there was no history of other malignant carcinomas. 7. the duration from the last chemotherapy was \>4 weeks, the duration from the last radiotherapy was \>6 weeks, and the duration from the last immunotherapy was \>6 weeks. 8. not allergic to cisplatin or doxorubicin. 9. the patients should be able to understand our research and sign the informed consent. exclusion criteria: 1. imaging or pathological examination shows tets without pleural spread or recurrence, or with pericardial dissemination or extrathoracic metastasis. 2. patients with lymphoid system, neurogenic or reproductive system carcinoma. 3. patients who have been receiving chemotherapy, radiotherapy, immunotherapy, or targeted therapy. 4. patients with myasthenia gravis in unstable or acute exacerbation stage. 5. the patients have been proven history of congestive heart failure, angina without good control with medicine; ecg-proved penetrating myocardial infarction; hypertension with bad control; valvulopathy with clinical significance; arrhythmia with high risk and out of control. 6. the patients have the severe systematic intercurrent disease, such as active infection or poorly controlled diabetes; coagulation disorders; hemorrhagic tendency or under-treatment of thrombolysis or anticoagulant therapy. 7. female who is positive for a serum pregnancy test or during lactation period. 8. the patients have a history of organ transplantation (including autologous bone marrow transplantation and peripheral stem cell transplantation. 9. the patients have a history of peripheral nerve system disorders, obvious mental disorders, or central nerve system disorders. 10. the patients attend other clinical trials.

Keywords: hyperthermic intrathoracic chemotherapy thymic epithelial malignancies
iguratimod combined with tofacitinib in the treatment of rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to assess the efficacy and safety of iguratimod combined with tofacitinib in the treatment of csdmard-ir patients with active moderate-to-severe rheumatoid arthritis

after being informed about the study and potential risks, all patients giving written informed consent will undergo a 1-week screening period to determine eligibility for study entry. at week 0, patients who meet the eligibility requirements will be randomized in a double-blind manner (participant and investigator) in a 1:1 ratio to iguratimod (25mg, twice daily) combined with tofacitinib (5mg, twice daily) or placebo (25mg, twice daily) combined with tofacitinib (5mg, twice daily).

Eligibility criteria:
inclusion criteria: patients who meet the following inclusion criteria will be eligible to participate in the study: 1. male or female aged 18-65 years old; 2. weight not less than 40kg; 3. since the diagnosis of ra, the course of disease was ≥6 months; 4. patients who meet ra standards in 1987 and 2010 ; 5. ra patients with moderate to high disease activity (das28 \> 3.2) at the time of screening; 6. active ra (≥6 joints swelling \[66 joints count\]; ≥tenderness of 6 joints \[68 joint counts\]; esr\>28 mm/h or c-reactive protein (crp) \>1.0 mg/dl); 7. poor response or intolerance to at least one dmard, including csdmards, bdmards, but not tsdmards; 8. previous use of any jak inhibitor was discontinued for six months before enrollment; 9. for patients who have used dmards, the washout criteria must be met; 10. written informed consent; exclusion criteria: patients who meet any of the following criteria will be excluded from the study: * pregnant or lactating women; * platelet count \< 10\^9/l, or white blood cell \< 3\*10\^9/l, or absolute neutrophil count \< 1.2\*10\^9/l, or hemoglobin \< 9 g/dl or hematocrit \<30%; * according to cockcroft-gault, the glomerular filtration rate was ≤40 ml/min. * alt\>1.5×uln, ast\>1.5×uln, cr\>135umol/l; * subjects with serious cardiovascular, renal, hematologic or endocrine diseases; * a history of autoimmune rheumatic diseases other than sjogren's syndrome; * subjects with uncontrolled infection; * subjects receiving live vaccines within 6 weeks prior to study entry; * history of alcohol or drug abuse and abstinence for less than 6 months prior to the first use of the study drug; * subjects participating in other clinical study within 3 months prior to study entry; * have a history of malignant tumor; * history of recurrent herpes zoster, diffuse herpes zoster; * people who are allergic to any of the study drugs; * other conditions in which the investigator deemed the patient inappropriate for trial entry;
a study to determine the safety and immunogenicity of co-administration of the candidate influenza vaccine mva-np+m1 and seasonal influenza vaccine

Conditions: Influenza

Summary: this is a single blinded placebo controlled phase i study, to assess the safety and immunogenicity of co-administration of the candidate influenza vaccine mva-np+m1 with seasonal influenza vaccine. all volunteers recruited will be adults aged 50 and over. the rationale behind co-administration of mva-np+m1 with a seasonal influenza vaccine (tiv) is that the immune system will be stimulated to produce both influenza specific t cells and influenza specific antibodies.


Eligibility criteria:
inclusion criteria: men and women aged 50 or over with no upper age limit * resident in or near oxford for the duration of the vaccination study * able and willing (in the investigators' opinions) to comply with all study requirements * willing to allow the investigators to discuss the volunteer's medical history with their general practitioner * for females who are not post-menopausal, a negative pregnancy test on the day of vaccination and agreement to practice effective contraception for the duration of the study * agreement to refrain from blood donation during the course of the study * written informed consent exclusion criteria: participation in another research study involving an investigational product in the 30 days preceding enrolment, or planned use during the study period * receipt of mva or smallpox vaccines in the last 5 years, or receipt of the 2011/12 seasonal influenza vaccine prior to entering the study. * administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate * any confirmed or suspected immunosuppressive or immunodeficient state, including hiv infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled/topical steroids are allowed) * history of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products * any history of anaphylaxis in reaction to vaccination * recent treatment for cancer (except basal cell carcinoma and cervical carcinoma in situ) * history of serious psychiatric condition * suspected or known current injecting drug or alcohol abuse (as defined by an alcohol intake of greater than 42 units every week) * seropositive for hepatitis b surface (hbsag) or hepatitis c virus (antibodies to hcv) * for pre-menopausal females, pregnancy, lactation or willingness/intention to become pregnant during the study * any other significant disease, disorder or finding (including blood test results), which, in the opinion of the investigators, would either put the volunteer at risk because of participation in the study, or may influence the result of the study. * no response / confirmation from gp regarding previous medical history
study to investigate long-term pulmonary and extrapulmonary effects of covid-19

Conditions: COVID-19

Summary: prospective observational swiss cohort study to investigate long-term pulmonary and extrapulmonary effects of covid-19.

covid-19 is a coronavirus induced viral pneumonia leading to acute respiratory distress syndrome. previous coronavirus infections (sars and mers) led to pulmonary fibrosis in up to 30%. prospective evaluation of lung abnormalities and pulmonary fibrosis after covid-19 infection is crucial as novel treatments against lung fibrosis of different etiologies are available. no data on pulmonary longterm effects in covid-19 survivors are currently available. the nation-wide swiss covid-19 lung group establishes a meticulously characterized prospective cohort study on pulmonary long-term sequela of patients living in switzerland.

Eligibility criteria:
inclusion criteria: * signed written informed consent. * all adult patients with covid-19 over 18 years. exclusion criteria: * severe mental or physical disability precluding informed consent or compliance with the protocol for prospective data collection. * pregnancy.

Keywords: covid-19 coronavirus infection lung abnormalities radiological abnormalities ards quality of life
a study to assess the effect of ym150 for prevention of venous thromboembolism in patients undergoing major abdominal surgery

Conditions: Venous Thromboembolism

Summary: the purpose of the study is to evaluate the efficacy and safety of the oral dose of ym150 for prevention of venous thromboembolism (vte) in patients undergoing major abdominal surgery.


Eligibility criteria:
inclusion criteria: * patients after a major abdominal surgery * written informed consent obtained exclusion criteria: * subject has history of symptomatic deep vein thrombosis and/or pulmonary embolism * subject has a hemorrhagic disorder and/or coagulation disorder * subject has had clinically important bleeding occurred within 90 days prior to the screening visit * subject has an active bacterial endocarditis * subject has uncontrolled severe or moderate hypertension, retinopathy, myocardial infarction or stroke * subject is receiving anticoagulants/antiplatelet agents * subject has a thrombocytopenia * body weight less than 40 kg at the screening

Keywords: ym150 bleeding vte fxa inhibitor deep vein thrombosis venous thromboembolism
allopurinol and endothelial function in diabetic cad patients

Conditions: Diabetes Mellitus; Coronary Artery Disease

Summary: this is a randomized trial assessing the impact of allopurinol on endothelial function in optimally treated diabetic patients with coronary artery disease. after initial screening, subjects were randomized to receive either optimal medical therapy (omt) + allopurinol or omt alone for 8 weeks. the dose of allopurinol was 300 mg for 4 weeks and 600 mg for 4 weeks with a 4-weekly check on hematology and biochemistry


Eligibility criteria:
inclusion criteria: * diabetes type 2 * known coronary artery disease with previous percutaneous coronary intervention and optimal medical therapy for at least one month exclusion criteria: * pregnant or breast- feeding women * creatinine clearance \<60ml/min * known history of gout disease or ongoing treatment with allopurinol * allergy to allopurinol * inability to provide informed consent

Keywords: allopurinol coronary artery disease diabetes endothelial function
synergistic treatment for hepatocellular carcinoma (hcc) using transcatheter arterial chemoembolization (tace) with anti-hepatitis b virus (anti-hbv) therapy

Conditions: Hepatocellular Carcinoma

Summary: the purpose of this study is to elucidate the influence of anti-hepatitis b virus therapy on safety and survival of hcc patient after transcatheter arterial chemoembolization.


Eligibility criteria:
inclusion criteria: * hepatocellular carcinoma * treated with transcatheter arterial chemoembolization (tace) * hbvdna \> 10\^3copies/ml, including alanine aminotransferase (alt) normal patient * expected survive time \> 1 year * hbv marker positive (anyone of hbsag, hbsab, hbeag, hbeab and hbcab) exclusion criteria: * antiviral therapy history * alanine aminotransferase (alt) \>400 u/l * serum total bilirubin \> 50 μmol/l * hbvdna \> 10\^9copies/ml * extrahepatic metastasis or main portal vein embolus * apparent cardiac or pulmonary dysfunction * liver function: child b or child c * hcv infection

Keywords: hepatitis b virus antiviral agents liver neoplasms drug toxicity survival
autologous patch healing vs. secondary intention healing after mohs micrographic surgery

Conditions: Skin Cancer; Basal Cell Carcinoma

Summary: the primary objects of this study is to explore the potential effect of the autologous patch to optimize wound healing after skin cancer surgery with mohs micrographic surgery (mms) in the face in a randomized controlled trial comparing autologous patch healing versus secondary intention healing.


Eligibility criteria:
inclusion criteria: 1. subjects undergoing mms for biopsy verified primary nodular basal cell carcinoma in the face, head and neck area on a location suitable for secondary intention healing and thus may also be suitable for autologous patch healing 2. presenting relevant medical record report at study initiation 3. written informed consent obtained from subject 4. understanding of investigation procedures and willingness to abide to all procedures during the course of the investigation. exclusion criteria: 1. a subjects with major systemic disease not yet stabilized 2. significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study. 3. pregnant or breast feeding 4. unable to follow the outlined study protocol 5. participation in other studies at the same time that may affect the wound healing.

Keywords: skin cancer basal cell carcinoma mohs micrographic surgery mms autologous patch secondary intention healing
investigation of the relationship between lower and upper extremity selective motor control and sensory functions in children with spastic cerebral palsy

Conditions: Spastic Cerebral Palsy; Motor Activity; Lower Extremity Problem; Upper Extremity Problem

Summary: although spasticity, contractures and muscle weakness in children with cp are disorders that can be observed more easily and are more focused and given more importance in evaluation and treatment approaches; inadequate or loss of selective motor control negatively affects motor functions to a greater extent. it is very important to reveal the causes and consequences of selective motor disability in children with spastic cerebral palsy, in terms of creating effective treatment plans. the number of patients to participate in the study was determined as 100. the study will be carried out in hatay mustafa kemal university research and application hospital, department of pediatrics. in our study, demographic information will be filled in, and lower extremity selective control assessment scale (scale) for lower extremity, upper extremity selective control scale (scues) for upper extremity, and sensory assessment (touch, two-point discrimination and proprioceptive sensory assessment) will be performed on the patients who accepted the study.


Eligibility criteria:
inclusion criteria: * giving consent to participate in the study * to be diagnosed with spastic type cerebral palsy; * being between the ages of 4-18; * being at level i-ii-iii according to the gross motor function classification system (gmfcs); * not having undergone botulinum toxin injection/lower-upper extremity surgery in the last 6 months exclusion criteria: * to be in level iv-v according to gross motor function classification system (gmfcs) * having severe mental retardation who does not understand verbal commands
surgical outcome of bcs using icg-f in breast cancer patients after preoperative chemotherapy

Conditions: Breast Neoplasms; Breast Cancer

Summary: neoadjuvant chemotherapy for advanced breast cancer has led to an increased rate of breast-conserving surgery (bcs) in these patients. as the demand for preoperative localization methods grows among surgeons performing bcs, traditional localization techniques have shown limitations. for non-palpable breast lesions, preoperative localization has commonly been achieved using ultrasound-guided skin markings or needle localization. however, these methods present challenges, including difficulty in depth localization for patients with large breasts and limitations in real-time re-verification during surgery due to air artifacts after incision. needle localization, although commonly used, is invasive and poses risks such as displacement or detachment of the needle. indocyanine green (icg), a fluorescent dye that appears green to the naked eye and is detectable by near-infrared (nir) cameras, has been widely and safely used in clinical practice via intravenous or subcutaneous administration. recently, icg combined with nir imaging has been adopted for sentinel lymph node biopsy in breast cancer and melanoma surgeries and is increasingly used as a localization method for various tumors, replacing conventional techniques. a preliminary study (irb no. ncc2016-0071) conducted at the institution evaluated icg injection and nir fluorescence imaging for tumor localization in early breast cancer patients undergoing bcs. the study demonstrated the efficacy of icg-based localization in reducing the rate of positive surgical margins. the objective of this study is to evaluate the effectiveness of icg-guided tumor localization with nir fluorescence imaging in patients with advanced breast cancer treated with neoadjuvant chemotherapy. it is hypothesized that this technique will allow for more accurate tumor excision compared to conventional methods, ultimately improving surgical outcomes.


Eligibility criteria:
inclusion criteria: * the patient with locally advanced breast cancer who is eligible for breast-conserving surgery after receiving neoadjuvant chemotherapy * aged over 18 years old * ecog performance status: 0 or 1 * the patients with written informed consent exclusion criteria: * the patient who requires total mastectomy after receiving neoadjuvant chemotherapy * the patient with no residual mass on ultrasonography or only with microcalcifications * pregnant or lactating patient * the patient with a disability to understand and provide consent * the patient with severe allergic history to indocyanine green * iodine-sensitive patient

Keywords: indocyanine green breast conserving surgery breast cancer neoadjuvant chemotherapy tumor localization near-infrared fluorescence imaging
efficacy of hydrotherapy on balance in neuropathic patients post-burn

Conditions: Neuropathy; Burn

Summary: balance problems are common among neuropathic patients following burns, primarily due to sensory and motor impairments.the goal of the study is to investigate the effect of a hydrotherapy program on balance in neuropathic patients following burns. it is a randomized controlled study will be conducted on fifty male patients (age range from 35 to 45 years) with polyneuropathy following lower limb burn injuries, mainly at the sole of the foot, with 3rd-degree injuries and 30% burn extent. balance will be assessed before and after treatment using the biodex balance system and the berg balance scale (bbs). patients will be randomly assigned into two equal groups: group a (study group) will receive hydrotherapy sessions including stretching, resistance, and balance exercises in water. group b (control group) will receive traditional land-based balance exercises only.


Eligibility criteria:
inclusion criteria: * polyneuropathy following burn injuries of the lower limb mainly at the sole of the foot. * 3rd-degree injuries and 30% burn extent. * patients' ages range from 35 to 45 years, * ability to understand instructions and following commands. exclusion criteria: * balance disturbances due to neurological disorders other than polyneuropathy (e.g., parkinson's disease, inner ear disorders, vestibular or cerebellar dysfunctions). * uncontrolled hypertension. * diabetes mellitus, * cognitive impairments * blindness. * deafness. * significant respiratory or cardiac conditions.